Related Experiment Video
Updated: Mar 8, 2026
06:29
Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
Published on: July 30, 2020
3.6K
Aurora kinases: novel therapy targets in cancers
Anqun Tang1, Keyu Gao1, Laili Chu1
1Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Jiangsu, China.
Oncotarget
|February 2, 2017
Summary
Aurora kinases are crucial for cell division and implicated in cancer development. Inhibiting these kinases (AKIs) shows promise in cancer therapy, potentially enhancing chemotherapy effectiveness.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Aurora kinases (AURKA, AURKB, AURKC) are serine/threonine kinases vital for cell division, regulating mitosis and meiosis.
- Dysregulation, including overexpression and gene amplification, is observed in various cancers.
- These kinases play a significant role in chromosomal segregation and embryonic development.
Purpose of the Study:
- To review the structure, localization, and physiological functions of Aurora kinases in mitosis.
- To elucidate the oncogenic role of Aurora kinases in tumorigenesis.
- To discuss the therapeutic potential of Aurora kinases inhibitors (AKIs) in combination with conventional cancer therapies.
Main Methods:
- Literature review of studies on Aurora kinases and their inhibitors.
- Analysis of the role of Aurora kinases in cell cycle regulation.
- Examination of preclinical and clinical data on AKIs in cancer treatment.
Main Results:
- Aurora kinases are essential for accurate mitosis and chromosomal segregation.
- Overexpression of Aurora kinases is a hallmark of many cancers, contributing to tumorigenesis.
- Aurora kinases inhibitors (AKIs) have demonstrated efficacy in repressing cancer progression in vitro and in vivo.
Conclusions:
- Aurora kinases represent a promising therapeutic target for cancer treatment.
- Inhibiting Aurora kinases can potentiate the efficacy of conventional chemotherapies.
- Combination therapy involving AKIs and standard treatments warrants further investigation for improved cancer outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:15M-Cdk Drives Transition Into Mitosis
6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
03:03mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
02:38Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K